Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function <i>NOTCH1</i>-Mutant Head and Neck CancerFaye M. Johnson, Mitchell J. Frederick, Jitesh D. Kawedia et al.|The Oncologist|2022Cited by 21
Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutationFilip Jankú, Alex A. Adjei, Faye M. Johnson et al.|Molecular Cancer Therapeutics|2019Cited by 7